| |
|
|
| |
EVENT DETAILS |
<P>Comemeet aspiring entrepreneurs, inventors, scientists, clinicians, engineers & business professionals. Network with future teammates for our December Pitch Day!</P>
<P><STRONG><A HREF="http://benchtobedsideinitiative.com/" TARGET="_blank" REL="noopener noreferrer noopener nofollow noopener noreferrer nofollow nofollow noreferrer nofollow">The</A><A HREF="http://benchtobedsideinitiative.com/" TARGET="_blank" REL="noopener noreferrer noopener nofollow noopener noreferrer nofollow nofollow noreferrer nofollow">Bench to Bedside Initiative</A></STRONG><SPAN><STRONG>(BBI)</STRONG>is supported in part by Weill Cornell Medicine Dean's Entrepreneurship Lab. This event is the beginning of our 12-week seminar series.</SPAN><SPAN>All attendees are encouraged to form teams & to write business plans around patented technologies invented at Cornell University, Memorial Sloan Kettering Cancer Center & Rockefeller University.</SPAN></P>
<P><EM><STRONG>[</STRONG>For earlybirds or inventors looking for team members:<STRONG>http://benchtobedsideinitiative.com-->build teams</STRONG><STRONG>]</STRONG></EM></P>
<P><SPAN><STRONG>Keynote: George D. Yancopoulos</STRONG>, MD, PhD,Co-founder, President & Chief Scientific Officer, Regeneron</SPAN></P>
<P><STRONG>Featuring three BBI alumni startups.</STRONG></P>
<P>5:30pm - 6pm: Registration</P>
<P>6:00pm: Presentations begin</P>
<P>7:30pm: Networking</P>
<P><SPAN><SPAN><STRONG>George D. Yancopoulos</STRONG>, MD, PhD, is Regenerons President & Chief Scientific Officer. In 1989, he joined Len Schleifer, MD, PhD, to launch Regeneron. George has been driven by science his entire life. He began his education at the Bronx High School of Science, received his MD & PhD from Columbia University & went on to become the 11th most highly cited scientist in the world in the 1990s. In 2004, he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor & developer of Regeneron's six FDA-approved drugs, as well as its foundational technologies, including the Trap technology, VelociGene</SPAN><SPAN></SPAN><SPAN>and VelocImmune</SPAN><SPAN></SPAN><SPAN>.</SPAN></SPAN></P>
|
|
|
|
|
|
